PATH | VRL
Menu

Comparative Evaluation of the Potential Impact of Rotavirus Versus HPV Vaccination in GAVI-Eligible Countries: A Preliminary Analysis Focused on the Relative Disease Burden

This article, published in BMC Infectious Diseases, reports on a study that aimed to provide early insight into how the comparative impact of different new vaccines could be assessed in resource-poor settings with respect to affordability, cost-effectiveness, and distributional equity. The authors used simple static models to standardize the analytic framework and improve comparability between the two vaccines: rotavirus and human papillomavirus (HPV). The results indicated that, while lifesaving benefits of rotavirus and HPV vaccines will be realized at different times, the number of lives saved over each target populations' lifetimes will be similar. And, although the new vaccines may be deemed cost-effective, other factors including affordability and distributional equity need to be considered in different settings.

Author: Kim SY, Sweet S, Chang J, Goldie SJ

Published: 2011

» Visit web page (English)

(Located at www.biomedcentral.com)

Citation: Kim SY, Sweet S, Chang J, Goldie SJ. Comparative Evaluation of the Potential Impact of Rotavirus Versus HPV Vaccination in GAVI-Eligible Countries: A Preliminary Analysis Focused on the Relative Disease Burden. BMC Infectious Diseases. 2011;11:174.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV), Rotavirus

Topics: Immunization financing, Disease burden and surveillance, Disease/vaccine specific information

Regions: Global